Which components belong in the assessment?
Map the actual drug-contact system before requesting analytical work. A cartridge, elastomeric stopper and other relevant contact components require different consideration from an external housing that never contacts the formulation.
Record the material grade, component supplier, processing history where relevant, contact conditions and configuration revision. Do not assume that an attractive metal housing is the most important material in the assessment. A coating, closure component or process change may deserve attention even when the exterior looks identical. The responsible analytical and toxicological teams should determine the appropriate study scope from the actual formulation and exposure context. Procurement’s role is to make those inputs traceable and to identify who supplies missing information. A generic description such as medical-grade plastic is not a complete material specification. Keep the material inventory connected to the container and device records used for the project’s compatibility and release decisions.
How do extractables and leachables evidence differ?
Extractables characterization and drug-product leachables assessment are related but do not produce interchangeable conclusions. USP <1663> and <1664> address these two assessment frameworks respectively; their chapter numbers are not product certificates.
An extraction study can help identify substances that warrant further consideration, while a product-specific assessment needs a justified link to the actual presentation and conditions. Ask the laboratory to explain how its scope supports that link. A chromatogram without method context, sample identity or interpretation cannot answer whether a proposed system is suitable. Analytical findings and their safety assessment are also distinct deliverables. Assign responsibility for interpreting results rather than treating a laboratory output as an automatic pass. This page does not prescribe solvents, extraction conditions, toxicological limits or a universal test panel. Those choices require competent project-specific assessment using the applicable references and intended exposure. Record assumptions and limitations beside the evidence.
What should buyers ask a laboratory or supplier to deliver?
Request an agreed study brief, traceable sample and method records, reported findings and the responsible interpretation route. The deliverable should explain its applicability and limitations rather than simply state that a material passed an E&L test.
The brief should identify the formulation owner, container and component owners, analytical provider and reviewer responsible for safety conclusions. Confirm which materials and revisions are included before a quotation is accepted. Ask how unidentified findings, missing inputs or proposed substitutions will be handled. Where existing supplier data are proposed for reuse, request a documented explanation of their relevance to the new presentation. Keep raw analytical information and the purchasing decision separate but linked. If a material, process or contact condition changes later, assess whether the justification still holds. A report should support a scoped decision about a defined system; it should not become a reusable marketing claim covering every injection pen in a catalogue.
Supplier evidence decision record
| Review area | Record to request | Purchasing question |
|---|---|---|
| Inventory | Contact component, material and revision | What is actually exposed to the formulation? |
| Study purpose | Extractables characterization or product leachables assessment | Which decision will the study support? |
| Applicability | Formulation and contact-condition assumptions | Why can this evidence be used for the proposed system? |
| Interpretation | Analytical findings and assessment owner | Who evaluates uncertainty and safety relevance? |
Questions buyers should resolve
Confirm which configuration and intended decision the evidence supports. Keep unknown inputs, report limitations and responsible reviewers visible before accepting a supplier statement.
Does a raw-material certificate prove a complete pen is suitable?
No. A raw-material document has its own scope. Suitability of a drug-contact system requires assessment of the actual materials, configuration, formulation and relevant conditions.
Can an extractables report be called a leachables report?
No. The study purposes differ. Ask which assessment was performed and how the evidence relates to the actual drug product and presentation.
Can supplier data be reused for another formulation?
Possibly, but only with a documented applicability assessment by the responsible team. A common component name does not establish equivalent contact conditions or a complete safety conclusion.
Sources and applicability
- USP: Quality standards for vaccines — summaries of <1663> and <1664> frameworks · Reference checked 23 October 2026
- FDA: Container closure packaging guidance — final, 1999 · Reference checked 23 October 2026
This article combines public reference scopes with original procurement analysis. It is not a laboratory protocol, a claim of product conformity or evidence that Hytanbio-Tech performed the illustrated tests. The responsible technical and regulatory teams determine the applicable requirements and assessment plan.